Genetic Screens in iPSC-derived Brain Cells

Genetic screening is a critical tool that can be employed to define and understand gene function and interaction. This feed focuses on genetic screens conducted using induced pluripotent stem cell (iPSC)-derived brain cells. It also follows CRISPR-Cas9 approaches to generating genetic mutants as a means of understanding the effect of genetics on phenotype.

January 19, 2019

Making NSC and Neurons from Patient-Derived Tissue Samples

Methods in Molecular Biology
Odity MukherjeeMahendra Rao
March 31, 2019
Open Access

LRRK2 modifies α-syn pathology and spread in mouse models and human neurons

Acta Neuropathologica
Gregor BieriAaron D. Gitler
November 18, 2020

Massively parallel techniques for cataloguing the regulome of the human brain

Nature Neuroscience
Kayla G TownsleyLaura M Huckins
November 7, 2019
Open Access

Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model

Scientific Reports
Gwenaëlle Le RouxAloïse Mabondzo
February 22, 2020
Open Access

Human-Induced Pluripotent Stem Cells and Herbal Small-Molecule Drugs for Treatment of Alzheimer's Disease

International Journal of Molecular Sciences
Wei WuliHorng-Jyh Harn
October 22, 2019
Open Access

Stem cell derived oligodendrocytes to study myelin diseases

Konstantina ChanoumidouTanja Kuhlmann
January 29, 2020
Open Access

Rescuing compounds for Lesch-Nyhan disease identified using stem cell-based phenotypic screening

JCI Insight
Valentin RuillierAlexandra Benchoua
April 6, 2019
Comment / Editorial
Open Access

Stars in the Night Sky: iPSC-Cardiomyocytes Return the Patient Context to Drug Screening

Cell Stem Cell
Anna Hnatiuk, Mark Mercola
December 20, 2020

3D Self-Organized Human Blood-Brain Barrier in a Microfluidic Chip

Methods in Molecular Biology
Marco CampisiRoger Dale Kamm
December 29, 2020
Open Access

Modeling Rett Syndrome With Human Patient-Specific Forebrain Organoids

Frontiers in Cell and Developmental Biology
Ana Rita GomesMaria Margarida Diogo
May 30, 2020

NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models

Molecular Psychiatry
Swagata GhatakStuart A Lipton
February 18, 2020

ASCL1- and DLX2-induced GABAergic neurons from hiPSC-derived NPCs

Journal of Neuroscience Methods
Natalie BarrettoKristen J Brennand
September 19, 2019
Open Access

A High-Content Screen Identifies TPP1 and Aurora B as Regulators of Axonal Mitochondrial Transport

Cell Reports
Evgeny ShlevkovThomas L Schwarz
January 16, 2019
Open Access

LRRK2 modifies α-syn pathology and spread in mouse models and human neurons

BioRxiv : the Preprint Server for Biology
Gregor BieriAaron D. Gitler
March 24, 2020
Open Access

Production and validation of human induced pluripotent stem cell line from sporadic amyotrophic lateral sclerosis (SALS)

Stem Cell Research
Jun MaHuixian Cui

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.


TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

© 2021 Meta ULC. All rights reserved